Psilocybin law changes
111 dated entries, newest first: laws, rulings, regulations and ballot measures, plus state bills that touch psilocybin with their latest status. Each links to its source. Bills checked 26 October 2026.
RSS feed for new entries.
2026
10 September 2026 Regulation Costa Rica
Costa Rica: regulation
The Ministry of Health published an updated list of substances under national control, under Reglamento 45161-S. Psilocybin and psilocin remain on Lista I of psychotropic substances, as in the October 2022 edition.
22 July 2026 Bill Massachusetts
Massachusetts: H.2203, An Act establishing a pilot program for access to regulated psilocybin
Would let the Department of Public Health run a psilocybin services pilot for adults with PTSD and other specified conditions. Status: Recommended ought to pass by Health Care Financing and referred to House Ways and Means.
9 July 2026 Bill Massachusetts
Massachusetts: H.4986, An Act relative to therapeutic psilocybin treatment centers
Public Health committee redraft of H.2506 and H.2532 to allow therapeutic psilocybin treatment centers. Status: Reported favorably and referred to Health Care Financing 28 January 2026; reporting date extended to 31 December 2026.
H.4986, An Act relative to therapeutic psilocybin treatment centers, Massachusetts Legislature
23 June 2026 Bill Louisiana
Louisiana: SB 43, Provides relative to psychedelic-assisted therapy
Creates the Psychedelic-Assisted Therapy Initiative to support clinical studies of psychedelic-assisted therapy, including psilocybin and ibogaine, for substance use and mental health conditions. Status: Became law without the Governor's signature, Act 956, effective 1 August 2026.
4 June 2026 Bill Colorado
Colorado: HB26-1325, Natural Medicine
Creates an ibogaine research pilot program of up to five sites in the Behavioral Health Administration and changes the natural medicine advisory board. Status: Became law; signed act dated 4 June 2026.
4 June 2026 Bill Connecticut
Connecticut: SB 191, An Act Concerning the Psychedelic-Assisted Therapy Pilot Program
Expands eligibility for the DMHAS psilocybin and MDMA therapy pilot to residents 18 and older and removes its automatic end on DEA approval. Status: Signed 4 June 2026 (Public Act 26-108), effective 1 July 2026.
15 May 2026 Bill Illinois
Illinois: SB 2772, Illinois Psilocybin Advisory Board Act
Would create a psilocybin advisory board in the Department of Financial and Professional Regulation to advise on psilocybin and associated services. Status: Passed Senate 41-13 on 7 May 2026; re-referred to House Rules Committee 15 May 2026.
SB2772, 104th General Assembly: Psilocybin Advisory Board, Illinois General Assembly
12 May 2026 Bill Georgia
Georgia: HB 717, Medical Practice Act; regulation of the administration of psychedelic-assisted treatment and therapy
Requires Medical Board rules and licensure for clinics providing psychedelic-assisted treatment and therapy. Status: Signed 12 May 2026 (Act 634), effective 1 July 2026.
12 May 2026 Bill Oklahoma
Oklahoma: HB 3834, Ibogaine clinical trials; Oklahoma Breakthrough Therapy Act
Funds state participation in multistate ibogaine drug development trials and bars professional discipline of medical professionals solely for recommending participation in ibogaine clinical trials; it does not address psilocybin. Status: Signed by the Governor 12 May 2026; effective 1 November 2026.
HB 3834 bill information, 2026 session, Oklahoma Legislature
11 May 2026 Bill Georgia
Georgia: HB 382, Controlled substances; Schedule I; psilocybin; revise a provision
Carves FDA-approved crystalline polymorph psilocybin drugs out of Schedule I so they follow DEA scheduling. Status: Signed 11 May 2026 (Act 476), effective 1 July 2026.
8 May 2026 Bill New York
New York: S5303A / A2142A, Medical Psilocybin Act
Would let patients with qualifying conditions such as treatment-resistant depression, PTSD, substance use disorders and end-of-life distress use psilocybin under a Department of Health program. Status: Amended and recommitted to Senate Health Committee.
Senate Bill S5303A (2025-2026), Medical Psilocybin Act, New York State Senate
7 May 2026 Bill Missouri
Missouri: HB 1717 (HCS HBs 1717 & 1643), Alternative Therapies
Would require a state-funded study of psilocybin and ibogaine therapy for veterans and first responders with PTSD, depression, substance use disorders or end-of-life needs, shielding enrolled participants from prosecution. Status: Passed House 2 April 2026; reported do pass in Senate, placed on informal calendar 7 May 2026; died at end of session.
HB 1717 (2026), Alternative Therapies, Missouri House of Representatives
7 May 2026 Bill New Hampshire
New Hampshire: HB 1809, Establishes a medical psilocybin advisory board to assess the advantages and disadvantages of psilocybin use for therapeutic purposes
As amended by the House, would have created a medical psilocybin advisory board. Status: Passed House with amendment 26 March 2026; Senate voted inexpedient to legislate, bill killed.
HB 1809-FN (2026), Establishes a medical psilocybin advisory board, New Hampshire General Court
5 May 2026 Bill North Carolina
North Carolina: SB 1018, The HEAL Act (Healing Through Evidence-Based Access to Lifesaving Care Act)
Would fund two competitive state research grants for psychedelic studies, including psilocybin, with participants 21 and older. Status: Re-referred to Senate Appropriations/Base Budget Committee.
Senate Bill 1018, The HEAL Act (2025-2026 Session), North Carolina General Assembly
1 May 2026 Bill Iowa
Iowa: HF 978, A bill for an act relating to the production and administration of psilocybin, and providing penalties
Would have created a regulated system to produce psilocybin and administer it to patients. Status: Passed House 21 April 2025; reported by Senate Ways and Means with amendment 1 May 2026; no Senate vote before adjournment.
28 April 2026 Bill Maryland
Maryland: HB 427, Task Force on Responsible Use of Natural Psychedelic Substances - Extension and Membership
Extends the psychedelics task force to the end of 2027 and requires an updated report by 31 October 2026. Status: Signed 28 April 2026, Chapter 207.
9 April 2026 Bill Minnesota
Minnesota: HF 4577, Psilocybin therapeutic use program established
Alternative therapeutic psilocybin program bill with an advisory committee and appropriation. Status: Re-referred to Veterans and Military Affairs Division 9 April 2026; died when the biennium ended.
9 April 2026 Bill Rhode Island
Rhode Island: H 7756, Relating to Food and Drugs - Uniform Controlled Substances Act
Earlier 2026 version of the same psilocybin possession and home-cultivation exemption, contingent FDA-linked medical rules, sunset 1 July 2028. Status: Withdrawn at sponsor's request.
2026 H 7756, bill text, State of Rhode Island General Assembly
6 April 2026 Bill Virginia
Virginia: SB 379, Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes
Directs the Board of Pharmacy to reschedule psilocybin consistent with federal scheduling once the FDA approves a formulation for administration by a health care professional in a health care setting. Status: Approved by Governor 6 April 2026 (Chapter 306), effective 1 July 2026.
6 April 2026 Bill Virginia
Virginia: HB 1347, Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes
Identical companion to SB 379. Status: Approved by Governor 6 April 2026 (Chapter 305), effective 1 July 2026.
2 April 2026 Bill Massachusetts
Massachusetts: H.4050, Adult use, support services, cultivation and taxation of psilocybin-containing fungi
Would create a regulated adult-use framework for psilocybin-containing fungi. Status: Sent to a study order (H.5318), effectively shelved.
27 March 2026 Bill Illinois
Illinois: HB 1143, Illinois CURE Act (Compassionate Use and Research of Entheogens Act)
Would create an Illinois Psilocybin Advisory Board and a regulated psilocybin framework and amend the Controlled Substances Act. Status: Re-referred to House Rules Committee under Rule 19(a) 27 March 2026.
HB1143, 104th General Assembly: Illinois CURE Act, Illinois General Assembly
27 March 2026 Bill Illinois
Illinois: HB 2992, Healing Opportunities through Psilocybin Equity (HOPE) Pilot Program Act
Would create a psilocybin pilot program and an Illinois Psilocybin Advisory Board in the Department of Financial and Professional Regulation. Status: Re-referred to House Rules Committee under Rule 19(a) 27 March 2026.
HB2992, 104th General Assembly: HOPE Pilot Program, Illinois General Assembly
27 March 2026 Bill West Virginia
West Virginia: SB 906, Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
Makes it lawful to prescribe, distribute and market an FDA-approved, DEA-rescheduled psilocybin drug (organic psilocybin substance or crystalline polymorph psilocybin). Status: Signed by the Governor 27 March 2026; effective 12 June 2026 (Chapter 249, Acts 2026).
SB 906 bill history, 2026 Regular Session, West Virginia Legislature
26 March 2026 Bill Massachusetts
Massachusetts: H.1858, An Act relative to removing criminal penalties for limited psilocybin possession
House version of the limited-possession decriminalization bill. Status: Sent to a study order (H.5281), effectively shelved.
19 March 2026 Bill South Carolina
South Carolina: S. 1039, Schedule I substances
Would add "substituted tryptamines" (a structural class including DMT and 5-MeO-DMT) to Schedule I in 44-53-190(D); psilocybin stays in Schedule I. Status: Referred to Senate Committee on Medical Affairs; no further action, died when the 2025-2026 session ended.
16 March 2026 Bill Minnesota
Minnesota: HF 2906, Psilocybin therapeutic use program established
Would create a supervised therapeutic psilocybin program for adults 21 and over with qualifying conditions and move psilocybin from Schedule I to Schedule IV. Status: Passed House Health Finance and Policy Committee, re-referred to Commerce Finance and Policy 16 March 2026; died when the 2025-2026 biennium ended.
13 March 2026 Bill Mississippi
Mississippi: SB 2056, Automatic scheduling of FDA-approved crystalline polymorph psilocybin
Automatically places an FDA-approved, DEA-scheduled crystalline polymorph psilocybin drug on the state schedules. Status: Signed 13 March 2026.
11 March 2026 Bill Mississippi
Mississippi: HB 563, Controlled substances; provide for automatic scheduling of psilocybin after federal scheduling
House version of automatic state scheduling of psilocybin after federal rescheduling. Status: Passed House; died on Senate calendar.
10 March 2026 Bill South Dakota
South Dakota: HB 1099, Reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance
Moves an FDA-approved crystalline polymorph psilocybin drug product from Schedule I to Schedule IV so it could be prescribed once federally approved and rescheduled. Status: Signed 10 March 2026 (2026 Session Laws, Chapter 149); passed House 58-7 on 9 February 2026.
2026 Session Laws, Chapter 149 (House Bill 1099), South Dakota Legislative Research Council
27 February 2026 Bill Rhode Island
Rhode Island: H 7925, Relating to Food and Drugs - Uniform Controlled Substances Act
Would exempt under one ounce of psilocybin held or shared by a person, or cultivated at home for personal use, and require the Department of Health to write rules for medical use if the FDA reschedules psilocybin; sunset 1 July 2028. Status: Referred to House Health and Human Services on introduction; no further action before the 2026 session ended.
2026 H 7925, bill text, State of Rhode Island General Assembly
26 February 2026 Bill Michigan
Michigan: SB 802, Controlled substances: conduct associated with qualified psychoactive substances; exempt from criminal penalties in certain circumstances
Would exempt non-commercial possession and use of certain entheogenic plants and fungi, including psilocybin, from criminal penalties. Status: Pending in Senate Regulatory Affairs Committee (referred 26 February 2026).
16 February 2026 Bill West Virginia
West Virginia: HB 5588, Therapeutic Psilocybin Act For Veterans And First Responders
Would establish a regulated framework for the medical use of psilocybin to treat post-traumatic stress disorder, with production licensing, testing labs and a verification system. Status: Referred to House Health and Human Resources on 16 February 2026; no further action, died when the 2026 regular session ended.
HB 5588 bill history, 2026 Regular Session, West Virginia Legislature
12 February 2026 Bill Virginia
Virginia: SB 740, Breakthrough Therapies for Veteran Suicide Prevention Act; fund and council established; report
Would create a fund to support clinical research and implementation of FDA Breakthrough Therapies for PTSD, treatment-resistant depression, major depressive disorder and traumatic brain injury (the summary does not name psilocybin). Status: Continued to 2027 in Senate Finance and Appropriations.
5 February 2026 Bill Iowa
Iowa: SF 2151, A bill for an act removing psilocybin and psilocyn from the list of schedule I controlled substances
Would have removed psilocybin and psilocyn from Schedule I. Status: Assigned to Senate Health and Human Services subcommittee 5 February 2026; died.
Bill History for Senate File 2151 (91st GA), Iowa Legislature
4 February 2026 Bill Washington
Washington: SB 5921, Concerning psilocybin
Washington Medical Psilocybin Act: would let licensed clinicians administer psilocybin to qualifying patients 18 and older in medical settings. Status: Passed Senate Health and Long-Term Care 3 February 2026; referred to Ways and Means 4 February 2026 and died there.
SB 5921 (2025-26) bill summary, Washington State Legislature
3 February 2026 Bill Vermont
Vermont: H.859, An act relating to psychedelic therapy and clinical drug development trials
Would have addressed psychedelic therapy and clinical drug development trials. Status: Read first time and referred to House Committee on Health Care on 3 Feb 2026; no further action, died at the end of the 2025-2026 biennium.
2 February 2026 Bill California
California: SB 751, Veterans and Former First Responders Research Pilot Program
Would have created psilocybin research pilots for veterans and former first responders in up to five counties. Status: Held in Senate Appropriations 23 May 2025; returned to Secretary of Senate under Joint Rule 56 (dead) 2 February 2026.
2 February 2026 Bill West Virginia
West Virginia: HB 4640, Relating to drug scheduling of FDA-approved psilocybin
Would have allowed FDA-approved organic or crystalline polymorph psilocybin drugs to be prescribed once rescheduled; the House version of the policy enacted through SB 906. Status: Reported by committee substitute 28 January 2026; left on first reading on the House Calendar from 2 February 2026, died when the session ended.
HB 4640 bill history, 2026 Regular Session, West Virginia Legislature
29 January 2026 Bill Massachusetts
Massachusetts: S.1113, An Act relative to removing criminal penalties for limited psilocybin possession
Would remove criminal penalties for possessing limited amounts of psilocybin. Status: Sent to a study order (S.2930), effectively shelved.
28 January 2026 Bill Kansas
Kansas: HB 2218, Amending the definition of psilocybin to exclude crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV
Would exclude crystalline polymorph psilocybin from the Schedule I definition of psilocybin and list it in Schedule IV. Status: Reported favorably as amended by House Health and Human Services 28 January 2026; left on House General Orders; died at end of 2025-2026 session.
28 January 2026 Bill New Hampshire
New Hampshire: HB 1796, Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions
Would have allowed psilocybin treatment in approved clinical settings for qualifying conditions. Status: House committee recommended inexpedient to legislate (11-7); died.
23 January 2026 Bill Pennsylvania
Pennsylvania: SB 1149, Amending The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control
On FDA approval, would schedule the pharmaceutical composition of synthetic psilocybin to match federal law, taking effect 30 days after publication of DEA rescheduling in the Pennsylvania Bulletin. Status: Referred to Senate Judiciary Committee 23 January 2026; no further action.
Senate Bill 1149, 2025-2026 Regular Session, Pennsylvania General Assembly
22 January 2026 Bill Iowa
Iowa: HF 2085, A bill for an act relating to the production and administration of psilocybin and providing penalties
Would have created a regulated psilocybin production and administration system. Status: Referred to House Health and Human Services; subcommittee meeting set for 26 January 2026 was cancelled; died.
Bill History for House File 2085 (91st GA), Iowa Legislature
22 January 2026 Bill West Virginia
West Virginia: HB 4721, Relating to scheduling of FDA-approved crystalline polymorph psilocybin
Would have added a provision on scheduling crystalline polymorph psilocybin approved by the FDA. Status: Referred to House Health and Human Resources, then Judiciary, on 22 January 2026; no further action, died when the session ended.
HB 4721 bill history, 2026 Regular Session, West Virginia Legislature
20 January 2026 Bill New Jersey
New Jersey: S2283, Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million
Creates a Department of Health pilot program funding three hospitals to conduct psilocybin research, plus an advisory board. Status: Signed 20 January 2026 as P.L.2025, c.296.
12 January 2026 Bill Washington
Washington: SB 5201, Concerning access to psychedelic substances
Would have legalized supervised adult use of psilocybin under a two-track Department of Health and Liquor and Cannabis Board framework. Status: Sent from Health and Long-Term Care without recommendation; no action in Labor and Commerce; reintroduced and retained in committee 12 January 2026, then died when the 2025-2026 biennium ended.
SB 5201 (2025-26) bill summary, Washington State Legislature
12 January 2026 Bill Washington
Washington: HB 1433, Concerning access to psychedelic substances
House companion to SB 5201 legalizing supervised adult psilocybin use. Status: Public hearing 5 February 2025; retained in House Health Care and Wellness Committee 12 January 2026, then died when the 2025-2026 biennium ended.
HB 1433 (2025-26) bill summary, Washington State Legislature
9 January 2026 Bill New York
New York: S1801A / A3845A, Psilocybin assisted therapy pilot program for veterans and first responders
Would create a state psilocybin-assisted therapy pilot for veterans and first responders with SUNY academic health centers and appropriate $5 million. Status: Amended and recommitted to Senate Health Committee.
7 January 2026 Bill New York
New York: S495 / A3775, Medical use of psilocybin; psilocybin-assisted therapy grant program
Would let licensed facilitators provide psilocybin-assisted therapy and fund grants for veterans, first responders and low-income people, appropriating $5 million. Status: In Senate Finance Committee.
1 January 2026 Law The Czech Republic
The Czech Republic: law
The psilocybin provisions of Act No. 270/2025 Coll. took effect. Psilocybin for medical use may be given only by a psychiatrist, under supervision, to patients over 18 in Ministry of Health psychiatric hospitals and hospital psychiatric departments licensed by the Ministry. The clinical guideline limits it to depression associated with cancer, clinically severe depression where prior treatment failed, and other severe life-threatening disorders where usual treatment fails. Retreat and recreational use remain illegal.
Zakon c. 270/2025 Sb., e-Sbirka, Ministry of the Interior of the Czech Republic
2025
3 November 2025 Bill New Hampshire
New Hampshire: HB 528, Amending the penalties for the possession and use of psilocybin for persons 18 years of age or older
Would have made a first adult psilocybin possession offense a violation and later offenses misdemeanors, with sales still illegal. Status: Passed House 26 March 2025; tabled in Senate 5 June 2025; inexpedient to legislate 3 November 2025.
31 July 2025 Regulation Germany
Germany: regulation
The Central Institute of Mental Health (Mannheim) announced that BfArM had approved a compassionate-use programme: individual adults with treatment-resistant depression can be treated with psilocybin at CIMH Mannheim and the OVID Clinic Berlin, only in justified exceptional cases. It is not a retreat pathway.
27 June 2025 Bill Arizona
Arizona: SB 1555, approved medication; rescheduling; controlled substance (introduced as psilocybin services; regulation; licensure)
Allows an FDA-approved crystalline polymorph psilocybin medicine to be prescribed once the DEA reschedules it out of Schedule I. Status: Signed 27 June 2025 (Chapter 231).
SB1555 bill status, 57th Legislature 1st Regular Session, Arizona State Legislature
25 June 2025 Bill Michigan
Michigan: HB 4686, Crimes: controlled substances; creating, manufacturing, possessing, or using psilocybin or psilocin; allow under certain circumstances
Would let adults with a PTSD diagnosis possess and use limited amounts of psilocybin without criminal penalty. Status: Pending in House Families and Veterans Committee (referred 25 June 2025).
20 June 2025 Law New Mexico
New Mexico: law
The Medical Psilocybin Act (SB 219), signed in April 2025, took effect. It creates a medical program for qualifying conditions; the Department of Health gives a target implementation date of 31 December 2026 and the statute requires the program by 31 December 2027. It is not an adult-use or retreat framework.
12 June 2025 Bill Louisiana
Louisiana: SR 186, Creates the Task Force on Alternative Therapies for Veterans
Senate resolution creating a task force to study alternative therapies, including psychedelic therapies, for Louisiana veterans. Status: Adopted by the Senate 11 June 2025; sent to Secretary of State.
11 June 2025 Bill Iowa
Iowa: HF 383, A bill for an act relating to the controlled substance crystalline polymorph psilocybin
Addressed the status of crystalline polymorph psilocybin under Iowa's controlled substances law. Status: Passed House 92-0 and Senate 47-0; vetoed by Governor 11 June 2025.
11 June 2025 Bill Texas
Texas: SB 2308, Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine
Creates a state-supported consortium framework for FDA clinical trials of ibogaine for opioid use disorder and related conditions (ibogaine, not psilocybin). Status: Signed by the Governor 11 June 2025, effective immediately.
SB 2308, 89th Legislature (R), bill history, Texas Legislature Online
10 June 2025 Bill Maine
Maine: LD 1034, An Act to Decriminalize Personal Possession of Therapeutic Amounts of Psilocybin for Adults
Would have removed criminal penalties for adults possessing small, therapeutic amounts of psilocybin. Status: Failed final enactment votes in both chambers; dead.
3 June 2025 Bill Colorado
Colorado: SB25-297, Implementation of CO Natural Medicine Initiative
Directs the health department to collect data on the health effects and impacts of natural medicine use. Status: Became law; signed act dated 3 June 2025.
SB25-297 Implementation of CO Natural Medicine Initiative, Colorado General Assembly
3 June 2025 Bill Nevada
Nevada: AB 378, Creates the Alternative Therapy Pilot Program
Would have created a state pilot program for supervised psychedelic therapy, including psilocybin, for eligible patients. Status: Re-referred to Assembly Ways and Means 16 April 2025; no further action, died 3 June 2025.
22 May 2025 Bill Oregon
Oregon: HB 2387, Relating to psilocybin; and declaring an emergency
Allows licensees of certain health professional regulatory boards to provide psilocybin services as licensed facilitators and makes OHA psilocybin investigation records confidential. Status: Signed 22 May 2025; 2025 Or. Laws ch. 147, effective on signing (emergency clause).
HB 2387 (2025 Regular Session), measure overview, Oregon State Legislature
20 May 2025 Bill Connecticut
Connecticut: HB 7065, An Act Concerning the Decriminalization of Possession of Small Amounts of Psilocybin
Would have decriminalized possession of small amounts of psilocybin. Status: Passed House 19 May 2025; placed on Senate calendar 20 May 2025; died at end of session.
19 May 2025 Bill Texas
Texas: HB 4014, Relating to a study on the use of psychedelic therapies in the treatment of certain conditions
Would have had the Health and Human Services Commission, with Baylor College of Medicine and Dell Medical School, study MDMA, psilocybin and ketamine therapies for PTSD, depression and co-occurring conditions. Status: Passed the House; referred to Senate Health & Human Services on 19 May 2025 and died when the regular session ended.
HB 4014, 89th Legislature (R), bill history, Texas Legislature Online
15 May 2025 Bill Florida
Florida: SB 700, Department of Agriculture and Consumer Services
Omnibus agriculture bill that, among other things, criminalized transporting, selling or giving away psilocybin mushroom spores and mycelium. Status: Approved by Governor 15 May 2025; Chapter 2025-22; effective 1 July 2025.
CS/CS/CS/SB 700 (2025), Department of Agriculture and Consumer Services, The Florida Senate
12 May 2025 Bill Pennsylvania
Pennsylvania: HB 1439, Amending The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control
On FDA approval, would schedule the pharmaceutical composition of crystalline polymorph psilocybin to match federal law, with notice in the Pennsylvania Bulletin within five business days of DEA rescheduling. Status: Referred to House Health Committee 12 May 2025; no further action.
House Bill 1439, 2025-2026 Regular Session, Pennsylvania General Assembly
6 May 2025 Bill Missouri
Missouri: HB 829, Alternative Therapies
Earlier version of the veterans psilocybin study bill. Status: Reported do pass by House committee; dropped from calendar 6 May 2025.
HB 829 (2025), Alternative Therapies, Missouri House of Representatives
7 April 2025 Bill New Mexico
New Mexico: SB 219, Medical Psilocybin Act
Creates a Department of Health medical psilocybin program for qualifying conditions, an advisory board, and exempts program use from the Controlled Substances Act. Status: Signed 7 April 2025, Laws 2025 chapter 73.
SB 219 (2025 Regular Session), Medical Psilocybin Act, New Mexico Legislature
2 April 2025 Bill Virginia
Virginia: SB 1135, Crystalline polymorph psilocybin; regulations for prescribing, etc.
Would have directed the Board of Pharmacy to allow prescribing, dispensing, possessing and using crystalline polymorph psilocybin after FDA approval and DEA rescheduling. Status: Vetoed by Governor 24 March 2025; veto sustained by Senate 2 April 2025.
31 March 2025 Regulation Colorado
Colorado: regulation
The Department of Revenue's Natural Medicine Division issued Colorado's first healing center licence, to The Center Origin. Operating also depends on local approvals and on licensed cultivation and testing.
27 March 2025 Bill West Virginia
West Virginia: HB 3343, Relating to scheduling of FDA-approved crystalline polymorph psilocybin
Would have made it lawful to prescribe, distribute and market crystalline polymorph psilocybin once approved by the FDA. Status: Passed House 26 March 2025 (Roll No. 197); referred to Senate Health and Human Resources 27 March 2025, died there.
HB 3343 bill history, 2025 Regular Session, West Virginia Legislature
26 March 2025 Bill North Dakota
North Dakota: SB 2064, Relating to the scheduling of controlled substances; and to declare an emergency
Board of Pharmacy scheduling update that reenacted N.D.C.C. 19-03.1-05, 19-03.1-09 and 19-03.1-11, the last of which lists COMP360 psilocybin in Schedule IV. Status: Passed Senate 47-0 and House 88-0; signed by the Governor and filed with the Secretary of State 26 March 2025.
SB 2064 bill overview, 69th Legislative Assembly (2025), North Dakota Legislative Branch
11 March 2025 Bill Vermont
Vermont: S.106, An act relating to continuing the Psychedelic Therapy Advisory Working Group
Would have continued the Psychedelic Therapy Advisory Working Group created by Act 126 of 2024. Status: Referred to Senate Committee on Health and Welfare on 11 Mar 2025; no further action, died at the end of the 2025-2026 biennium.
7 March 2025 Bill Utah
Utah: S.B. 248, Controlled Substances Amendments
Would have amended the psilocybin and MDMA treatment provisions, provided for automatic rescheduling of a certain type of psilocybin if rescheduled federally, and extended a repeal date. Status: Enacting clause struck and filed in the Senate (died).
S.B. 248 Controlled Substances Amendments, 2025 General Session, Utah State Legislature
28 February 2025 Bill Vermont
Vermont: H.452, An act relating to decriminalization of psilocybin-containing mushrooms and the establishment of the Psilocybin Therapeutic Consultation Program
Would have decriminalized psilocybin-containing mushrooms and created a Psilocybin Therapeutic Consultation Program. Status: Read first time and referred to House Committee on Human Services on 28 Feb 2025; no further action, died at the end of the 2025-2026 biennium.
12 February 2025 Bill Iowa
Iowa: HF 351, A bill for an act removing psilocybin and psilocyn from the list of schedule I controlled substances
Would have removed psilocybin and psilocyn from Schedule I. Status: Referred to House Public Safety 12 February 2025; died.
11 February 2025 Bill Rhode Island
Rhode Island: H 5186, Relating to Food and Drugs - Uniform Controlled Substances Act
Would exempt under one ounce of psilocybin held, shared or cultivated at home for personal use, with Department of Health medical rules contingent on FDA action; sunset 1 July 2027. Status: House Judiciary recommended the measure be held for further study; died at end of 2025 session.
2025 H 5186, bill text, State of Rhode Island General Assembly
23 January 2025 Bill Connecticut
Connecticut: HB 6380, An Act Decriminalizing the Possession of Psilocybin
Would have decriminalized possession of psilocybin. Status: Referred to Judiciary Committee 23 January 2025; died in committee.
22 January 2025 Bill Connecticut
Connecticut: SB 855, An Act Concerning Funding for the Psychedelic-Assisted Therapy Pilot Program
Would have appropriated funding for the psychedelic-assisted therapy pilot program. Status: Referred to Appropriations Committee 22 January 2025; died in committee.
17 January 2025 Bill Connecticut
Connecticut: HB 5456, An Act Allowing the Use of Psilocybin for Medicinal and Therapeutic Purposes
Would have allowed psilocybin use for medicinal and therapeutic purposes. Status: Referred to Public Health Committee 17 January 2025; died in committee.
8 January 2025 Bill Indiana
Indiana: HB 1166, Appropriation for psilocybin research
Would have appropriated money from the state general fund to the therapeutic psilocybin research fund. Status: Referred to House Ways and Means 8 January 2025; died at end of 2025 session.
House Bill 1166 (2025), Appropriation for psilocybin research, Indiana General Assembly
2024
30 November 2024 Bill California
California: SB 1012, The Regulated Psychedelic Facilitators Act and the Regulated Psychedelic-Assisted Therapy Act
Would have created regulated, supervised adult use of certain psychedelics. Status: Held in Senate Appropriations 16 May 2024; died.
20 November 2024 Bill Maine
Maine: LD 1914, An Act to Enact the Maine Psilocybin Health Access Act
Would have created a regulated psilocybin services program. Status: Died in possession of the Senate at adjournment.
Summary of LD 1914, An Act to Enact the Maine Psilocybin Health Access Act, Maine Legislature
13 November 2024 Court ruling Mexico
Mexico: court ruling
The First Chamber of the Supreme Court (Amparo en Revision 179/2024, unanimous) denied an amparo seeking authorisation for personal recreational use of psilocybin and held the Ley General de Salud provisions that prohibit it (arts. 245 fr. I, 247, 248 and 249) constitutional.
Amparo en Revision 179/2024 (sentencia, Primera Sala), Suprema Corte de Justicia de la Nacion
November 2024 Ballot measure Oregon
Oregon: ballot measure
Local bans on psilocybin businesses passed in 16 of the 17 Oregon places that voted on them in the November 2024 election.
Psilocybin bans were on the ballot in 17 places in Oregon. They passed in all but one, OPB
19 September 2024 Bill Alaska
Alaska: HB 228, Mental Health/Psychedelic Med. Task Force
Established a legislative task force to prepare for regulation of FDA-approved psychedelic medicines. Status: Became law without the governor's signature 19 September 2024 (Chapter 60, SLA 2024).
HB 228, 33rd Legislature: Mental Health/Psychedelic Med. Task Force, Alaska State Legislature
23 August 2024 Official guidance Jamaica
Jamaica: official guidance
The Ministry of Health and Wellness said it has not approved psilocybin mushroom products for use on the Jamaican market and warned that they can be dangerous to health. Psilocybin mushrooms remain unlisted in the Dangerous Drugs Act.
Full Text | Health ministry warns against magic mushrooms, Jamaica Gleaner
18 June 2024 Bill Arizona
Arizona: SB 1570, psilocybin services; regulation; licensure
Would have created licensed psilocybin services. Status: Vetoed 18 June 2024.
SB1570 bill status, 56th Legislature 2nd Regular Session, Arizona State Legislature
29 May 2024 Bill Vermont
Vermont: S.114, An act relating to the establishment of the Psychedelic Therapy Advisory Working Group
Created the Psychedelic Therapy Advisory Working Group (Act 126). Status: Signed by the Governor 29 May 2024 (Act 126), effective 1 July 2024.
16 May 2024 Bill Maryland
Maryland: HB 548, Task Force on Responsible Use of Natural Psychedelic Substances
Created the task force to recommend an affordable, equitable access program for natural psychedelics. Status: Signed 16 May 2024, Chapter 792.
15 April 2024 Bill Wisconsin
Wisconsin: AB 753, Creating a medicinal psilocybin treatment fund and a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome at the University of Wisconsin-Madison, and making an appropriation
Would have funded a UW-Madison pilot study of psilocybin treatment for treatment-resistant PTSD with a new medicinal psilocybin treatment fund. Status: Failed to pass pursuant to Senate Joint Resolution 1 (died in Assembly Health, Aging and Long-Term Care Committee).
15 April 2024 Bill Wisconsin
Wisconsin: SB 727, Creating a medicinal psilocybin treatment fund and a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome at the University of Wisconsin-Madison, and making an appropriation
Senate companion to AB 753, creating a psilocybin PTSD pilot study at UW-Madison and a treatment fund. Status: Failed to pass pursuant to Senate Joint Resolution 1 (died in Senate Universities and Revenue Committee).
1 April 2024 Law Mexico
Mexico: law
Article 195 bis fraction II of the Federal Penal Code was reformed. The text in force bars federal prosecution for possession of peyote or hallucinogenic mushrooms for the ceremonies of Indigenous and Afro-Mexican communities recognised by their own authorities. It does not authorise supply or retreats for visitors.
13 March 2024 Bill Indiana
Indiana: HB 1259, Health care matters
Established the therapeutic psilocybin research fund and set clinical study requirements for grant recipients. Status: Signed 13 March 2024 (Public Law 152).
House Bill 1259 (2024), Health care matters, Indiana General Assembly
1 February 2024 Bill Rhode Island
Rhode Island: H 7047, Relating to Food and Drugs - Uniform Controlled Substances Act
Would have permitted possession of less than one ounce of psilocybin and secure home cultivation for personal use. Status: House Judiciary recommended the measure be held for further study; died at end of 2024 session.
2024 Regulation The Bahamas
The Bahamas: regulation
The Dangerous Drugs (Application) Order, 2024 applies Part IV of the Dangerous Drugs Act to the drugs in the schedules of the 1961 Single Convention and the 1971 Psychotropic Convention, which include psilocybine.
Dangerous Drugs (Application) Order, 2024, Office of the Attorney General, The Bahamas
2023
7 October 2023 Bill California
California: SB 58, Controlled substances: decriminalization of certain hallucinogenic substances
Would have decriminalized personal possession of psilocybin, psilocyn, DMT and mescaline (excluding peyote) for adults. Status: Vetoed 7 October 2023; veto sustained 25 January 2024.
1 July 2023 Regulation Australia
Australia: regulation
Psilocybine for treatment-resistant depression became a Schedule 8 medicine in the Poisons Standard, prescribable only by psychiatrists authorised by the TGA under the Authorised Prescriber scheme, with ethics committee approval.
23 May 2023 Law Colorado
Colorado: law
SB23-290 (Natural Medicine Regulation and Legalization) was signed. It sets up licensing of facilitators (Department of Regulatory Agencies) and natural medicine businesses (Department of Revenue), limits 'natural medicine' to psilocybin and psilocyn unless regulators add DMT, mescaline or ibogaine on or after 1 June 2026, and expressly excludes peyote.
29 March 2023 Bill Oklahoma
Oklahoma: HB 2107, Controlled dangerous substances; authorizing certain scientific research and clinical trials related to psilocybin and psilocyn; requiring registration; providing certain immunities
Would have authorized registered research and clinical trials of psilocybin and psilocyn with immunity for participants and researchers. Status: Passed House 66-32 on 9 March 2023; referred to Senate Health and Human Services and Appropriations on 29 March 2023 with no further action; died when the 59th Legislature adjourned in 2024.
HB 2107 bill information, 2023 session, Oklahoma Legislature
27 February 2023 Official guidance Canada
Canada: official guidance
Health Canada published a notice describing Special Access Program requests involving psychedelic-assisted psychotherapy as case-by-case and patient-specific, with the drug used in the practitioner's presence.
2 January 2023 Regulation Oregon
Oregon: regulation
The Oregon Health Authority opened licence applications for psilocybin service centers, facilitators, manufacturers and laboratories under OAR chapter 333, division 333. Licensed service centers began opening to clients in summer 2023.
2022
November 2022 Ballot measure Colorado
Colorado: ballot measure
Voters approved Proposition 122, the Natural Medicine Health Act, which added Article 170 to Title 12 of the Colorado Revised Statutes.
Initiative 58 final text (became Proposition 122), Colorado Secretary of State
November 2022 Ballot measure Oregon
Oregon: ballot measure
Under ORS 475A.718 local opt-outs, 25 counties and 26 cities banned psilocybin businesses at the November 2022 election, as OPB reported.
Oregon Psilocybin Services - Local Government Information, Oregon Health Authority
5 January 2022 Regulation Canada
Canada: regulation
Amendments (SOR/2021-271) came into force letting practitioners request restricted drugs such as psilocybin through the Special Access Program for patients with serious or life-threatening conditions.
2021
18 July 2021 Official guidance Jamaica
Jamaica: official guidance
The Jamaica Information Service quoted Agriculture Minister Floyd Green saying psilocybin was never made illegal in Jamaica and that it is legal to grow it, with interim protocols routing participants through the Plant Quarantine Division.
Protocols in Place for 'Magic Mushrooms', Jamaica Information Service
2020
November 2020 Ballot measure Oregon
Oregon: ballot measure
Voters approved Ballot Measure 109, codified as ORS 475A, directing the Oregon Health Authority to license and regulate psilocybin products and psilocybin services.
2011
28 December 2011 Official guidance The Netherlands
The Netherlands: official guidance
Answering parliamentary questions, Health Minister Schippers wrote that psychedelic truffles (sclerotia) do not fall under the Opium Act, and that this was known when mushrooms were placed on List II in 2008.
Aanhangsel Handelingen II 2011-2012, nr. 1032 (Kamervragen), Overheid.nl Officiele bekendmakingen
2008
1 December 2008 Law The Netherlands
The Netherlands: law
The Decree of 17 November 2008 (Staatsblad 2008, 486) came into force, adding hallucinogenic mushrooms, fresh or dried, to List II of the Opium Act. Truffles (sclerotia) are not covered.
Staatsblad 2008, 486 - Besluit van 17 november 2008, Overheid.nl Officiele bekendmakingen
2000
29 November 2000 Law Portugal
Portugal: law
Lei n.o 30/2000 made consumption, acquisition and possession for personal use of controlled substances an administrative offence rather than a crime. Supply remains drug trafficking.
Lei n.o 30/2000, de 29 de Novembro, Diario da Republica, I Serie-A, n.o 276
Back to the law map. A summary of published sources, not legal advice.